AI assistant
Sending…
Entera Bio Ltd. — Director's Dealing 2022
Feb 8, 2022
35604_dirs_2022-02-08_9fe69b96-d46c-4726-8915-331ca7ca3a02.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Entera Bio Ltd. (ENTX)
CIK: 0001638097
Period of Report: 2022-01-01
Reporting Person: Yaacov-Garbeli Dana (Israel CFO)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $2.14 | 2030-03-16 | Ordinary Shares, par value NIS 0.0000769 per share (35000) | Direct | |
| Stock Option (right to buy) | $3.15 | 2031-04-21 | Ordinary Shares, par value NIS 0.0000769 per share (120000) | Direct |
Footnotes
F1: The options vest over a four-year period that commenced on March 16, 2020, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
F2: The options vest over a four-year period that commenced on April 21, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
More from Entera Bio Ltd.
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 8
Regulatory Filings
2026
Mar 25
Regulatory Filings
2026
Mar 4
Director's Dealing
2026
Feb 17
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 9